148 related articles for article (PubMed ID: 7474937)
1. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.
Kesari S; Randazzo BP; Valyi-Nagy T; Huang QS; Brown SM; MacLean AR; Lee VM; Trojanowski JQ; Fraser NW
Lab Invest; 1995 Nov; 73(5):636-48. PubMed ID: 7474937
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
3. Proliferation, cell death, and neuronal differentiation in transplanted human embryonal carcinoma (NTera2) cells depend on the graft site in nude and severe combined immunodeficient mice.
Miyazono M; Lee VM; Trojanowski JQ
Lab Invest; 1995 Aug; 73(2):273-83. PubMed ID: 7637328
[TBL] [Abstract][Full Text] [Related]
4. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas.
Herrlinger U; Woiciechowski C; Sena-Esteves M; Aboody KS; Jacobs AH; Rainov NG; Snyder EY; Breakefield XO
Mol Ther; 2000 Apr; 1(4):347-57. PubMed ID: 10933953
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
6. Transplanted human neurons derived from a teratocarcinoma cell line (NTera-2) mature, integrate, and survive for over 1 year in the nude mouse brain.
Kleppner SR; Robinson KA; Trojanowski JQ; Lee VM
J Comp Neurol; 1995 Jul; 357(4):618-32. PubMed ID: 7673487
[TBL] [Abstract][Full Text] [Related]
7. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant.
Randazzo BP; Kesari S; Gesser RM; Alsop D; Ford JC; Brown SM; Maclean A; Fraser NW
Virology; 1995 Aug; 211(1):94-101. PubMed ID: 7645240
[TBL] [Abstract][Full Text] [Related]
8. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model.
Miller CG; Fraser NW
Cancer Res; 2000 Oct; 60(20):5714-22. PubMed ID: 11059765
[TBL] [Abstract][Full Text] [Related]
9. Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase.
Moriuchi S; Oligino T; Krisky D; Marconi P; Fink D; Cohen J; Glorioso JC
Cancer Res; 1998 Dec; 58(24):5731-7. PubMed ID: 9865731
[TBL] [Abstract][Full Text] [Related]
10. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
12. Neurons derived from a human teratocarcinoma cell line establish molecular and structural polarity following transplantation into the rodent brain.
Trojanowski JQ; Mantione JR; Lee JH; Seid DP; You T; Inge LJ; Lee VM
Exp Neurol; 1993 Aug; 122(2):283-94. PubMed ID: 8405265
[TBL] [Abstract][Full Text] [Related]
13. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
[TBL] [Abstract][Full Text] [Related]
14. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm.
Rainov NG; Kramm CM; Aboody-Guterman K; Chase M; Ueki K; Louis DN; Harsh GR; Chiocca A; Breakefield XO
Cancer Gene Ther; 1996; 3(2):99-106. PubMed ID: 8729908
[TBL] [Abstract][Full Text] [Related]
15. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Caparelli D; Benjamin I; Kaiser LR; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 1999 Jun; 5(6):1523-37. PubMed ID: 10389942
[TBL] [Abstract][Full Text] [Related]
16. HSV-tk gene therapy for human renal cell carcinoma in nude mice.
Pulkkanen KJ; Parkkinen JJ; Laukkanen JM; Kettunen MI; Tyynela K; Kauppinen RA; Ala-Opas MY; Yla-Herttuala S
Cancer Gene Ther; 2001 Jul; 8(7):529-36. PubMed ID: 11498775
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
18. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin.
Mullen JT; Donahue JM; Chandrasekhar S; Yoon SS; Liu W; Ellis LM; Nakamura H; Kasuya H; Pawlik TM; Tanabe KK
Cancer; 2004 Aug; 101(4):869-77. PubMed ID: 15305421
[TBL] [Abstract][Full Text] [Related]
19. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
20. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
